IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 472 
Small font sizeDefault font sizeIncrease font size
Navigate Here
  »   My Preferences 
  »   Manuscript submission

 


This article has been cited by
1
Pablo Duarte,Antonio Cuadrado,Rafael León
.2020;()
[DOI]
2Classical neurotransmitters and neuropeptides involved in generalized epilepsy in a multi-neurotransmitter system: How to improve the antiepileptic effect?
Felix-Martin Werner,Rafael Coveñas
Epilepsy & Behavior.2017;71()124
[DOI]
3An evaluation of zonisamide, including its long-term efficacy, for the treatment of focal epilepsy
Arne Reimers,Hanna Ljung
Expert Opinion on Pharmacotherapy.2019;20(8)909
[DOI]
4Zonisamide Enhances Motor Effects of Levodopa, Not of Apomorphine, in a Rat Model of Parkinson’s Disease
Haruo Nishijima,Yasuo Miki,Shinya Ueno,Masahiko Tomiyama
Parkinson's Disease.2018;2018(8)1
[DOI]
5Drugs related to monoamine oxidase activity
Zdenek Fišar
Progress in Neuro-Psychopharmacology and Biological Psychiatry.2016;69(8)112
[DOI]
6Extrastriatal spreading of microglial activation in Parkinson’s disease: a positron emission tomography study
Tatsuhiro Terada,Masamichi Yokokura,Etsuji Yoshikawa,Masami Futatsubashi,Satoshi Kono,Takashi Konishi,Hiroaki Miyajima,Takanori Hashizume,Yasuomi Ouchi
Annals of Nuclear Medicine.2016;30(8)579
[DOI]
7The agony of the agonists: a review of impulsivity and withdrawal syndromes in Parkinson's disease treatment
Andrea J Lindahl,Douglas G MacMahon
Future Neurology.2015;10(4)357
[DOI]
8The safety of medications used to treat peripheral neuropathic pain, part 1 (antidepressants and antiepileptics): review of double-blind, placebo-controlled, randomized clinical trials
Marie Selvy,Mélissa Cuménal,Nicolas Kerckhove,Christine Courteix,Jérôme Busserolles,David Balayssac
Expert Opinion on Drug Safety.2020;19(6)707
[DOI]
9The anti-parkinsonian drug zonisamide reduces neuroinflammation: Role of microglial Nav 1.6
Muhammad M. Hossain,Blair Weig,Kenneth Reuhl,Marla Gearing,Long-Jun Wu,Jason R. Richardson
Experimental Neurology.2018;308(6)111
[DOI]
10Neuroprotection as a Potential Therapeutic Perspective in Neurodegenerative Diseases: Focus on Antiepileptic Drugs
D. Caccamo,L. R. Pisani,P. Mazzocchetti,R. Ientile,P. Calabresi,F. Pisani,C. Costa
Neurochemical Research.2016;41(1-2)340
[DOI]
11Neuroprotection as a Potential Therapeutic Perspective in Neurodegenerative Diseases: Focus on Antiepileptic Drugs
F.-M. Werner,R. Coveñas
Neurochemical Research.2017;41(1-2)340
[DOI]
12Neuroprotection as a Potential Therapeutic Perspective in Neurodegenerative Diseases: Focus on Antiepileptic Drugs
Yoshikuni Mizuno
Neurochemical Research.2020;41(1-2)1
[DOI]
13Neuroprotection as a Potential Therapeutic Perspective in Neurodegenerative Diseases: Focus on Antiepileptic Drugs
Josef Finsterer
Neurochemical Research.2016;240(1-2)473
[DOI]
14Zonisamide inhibits monoamine oxidase and enhances motor performance and social activity
Maiko T. Uemura,Takeshi Asano,Rie Hikawa,Hodaka Yamakado,Ryosuke Takahashi
Neuroscience Research.2017;124(1-2)25
[DOI]
15Rational drug discovery design approaches for treating Parkinson’s disease
Cornelis J Van der Schyf
Expert Opinion on Drug Discovery.2015;10(7)713
[DOI]
Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow